IMPROVED SURVIVAL OF INCREASED-RISK MYELOMA PATIENTS ON COMBINED TRIPLE-ALKYLATING-AGENT THERAPY - STUDY OF THE CALGB

Google Scholar
  • 1 January 1979
    • journal article
    • research article
    • Vol. 54  (1) , 13-22
Abstract
Previously untreated evaluable patients (252) with multiple myeloma were entered into a study testing a regimen of 3 i.v. alkylating agents, melphalan, cyclophosphamide and carmustine (BCNU), given in combination (BCMP) against a regimen employing oral melphalan (MP). Both regimens included a tapering course of prednisone. Objective responses based on the Myeloma Task Force criteria were significantly more frequent in the group receiving BCMP. Survival for the entire group of BCMP-treated patients was not significantly better than that for MP-treated patients (P = 0.62). When the survival of the poor-risk (high tumor cell load) group of patients treated with BCMP was compared with the survival of the poor-risk (high tumor cell load) group of patients treated with MP, an improvement in survival attributable to BCMP therapy was seen (P = 0.049 and 0.02, respectively). In the good-risk (low and intermediate tumor cell load) group, BCMP treatment resulted in a trend toward poorer survival, but this did not achieve statistical significance (P = 0.080 and 0.23, respectively). These results indicate that optimal therapy in myeloma may be dependent on the extent of disease at the time of first treatment. Additional studies to explore the effects of treatment intensity and duration are needed to design improved myeloma treatment based on the patient''s extent of disease.